WALTHAM, Mass. – BG Medicine (NASDAQ: BGMD) announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine’s common stock at $7.00 per share, less underwriting discounts and commissions. BG Medicine also announced that it has closed its initial public offering of 5,750,000 shares of common stock at a public offering price of $7.00 per share, which included the sale of the shares pursuant to the over-allotment option.
Lazard Capital Markets LLC acted as the sole bookrunning manager for the initial public offering, and Baird and Cowen and Company acted as co-managers.
A registration statement relating to the offering was declared effective by the Securities and Exchange Commission on February 3, 2011. The offering was made solely by means of a written prospectus, copies of which may be obtained from Lazard Capital Markets LLC by mail at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, Attention: Syndicate Department, or by calling toll-free (800) 542-0970.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BG Medicine (www.bg-medicine.com)
BG Medicine (NASDAQ: BGMD) is a publicly-traded life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare. The Company’s lead product, the BGM Galectin-3 test for heart failure, measures galectin-3 levels in blood plasma or serum. Galectin-3 is a protein that has been shown to play an important role in heart failure, which is a leading cause of death. The Company is also developing three other diagnostic product candidates for cardiovascular disease, including (i) a second indication of its galectin-3 test as a predictor of heart failure development in patients following heart attack or a related condition called unstable angina, a serious form of cardiac chest pain; (ii) AMIPredict, to identify patients with a high risk of suffering a heart attack or stroke within the following two to four years; and (iii) LipidDx, a novel protein biomarker, to aid in the management of common lipid disorders.
Michael W. Rogers, 781-890-1199
EVP & Chief Financial Officer